Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 276

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial

Open access
Fleischer, David M., Greenhawt, Matthew, Sussman, Gordon, Bégin, Philippe, Nowak-Wegrzyn, Anna, Petroni, Daniel, Beyer, Kirsten, Brown-Whitehorn, Terri, Hebert, Jacques, Hourihane, Jonathan O’B, Campbell, Dianne E., Leonard, Stephanie, Chinthrajah, R. Sharon, Pongracic, Jacqueline A., Jones, Stacie M., Lange, Lars, Chong, Hey, Green, Todd D., Wood, Robert, Cheema, Amarjit, Prescott, Susan L., Smith, Peter, Yang, William, Chan, Edmond S., Byrne, Aideen, Assa’ad, Amal, Bird, J. Andrew, Kim, Edwin H., Schneider, Lynda, Davis, Carla M., Lanser, Bruce J., Lambert, Romain, Shreffler, Wayne · 2019 · JAMA

Abstract

Importance: There are currently no approved treatments for peanut allergy. Objective: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut-allergic children. Design, Setting, and Participants: Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, and August 18, 2017. Participants included peanut-allergic children (aged 4-11 years [n = 356] without a history of a severe anaphylactic reaction) developing objective symptoms during a double-blind, placebo-controlled food challenge at an eliciting dose of 300 mg or less of peanut protein. Interventions: Daily treatment with peanut patch containing either 250 μg of peanut protein (n = 238) or placebo (n = 118) for 12 months. Main Outcomes and Measures: The primary outcome was the percentage difference in responders between the peanut patch and placebo patch based on eliciting dose (highest dose at which objective signs/symptoms of an immediate hypersensitivity reaction developed) determined by food challenges at baseline and month 12. Participants with baseline eliciting dose of 10 mg or less were responders if the posttreatment eliciting dose was 300 mg or more; participants with baseline eliciting dose greater than 10 to 300 mg were responders if the posttreatment eliciting dose was 1000 mg or more. A threshold of 15% or more on the lower bound of a 95% CI around responder rate difference was prespecified to determine a positive trial result. Adverse event evaluation included collection of treatment-emergent adverse events (TEAEs). Results: Among 356 participants randomized (median age, 7 years; 61.2% male), 89.9% completed the trial; the mean treatment adherence was 98.5%. The responder rate was 35.3% with peanut-patch treatment vs 13.6% with placebo (difference, 21.7% [95% CI, 12.4%-29.8%; P < .001]). The prespecified lower bound of the CI threshold was not met. TEAEs, primarily patch application site reactions, occurred in 95.4% and 89% of active and placebo groups, respectively. The all-causes rate of discontinuation was 10.5% in the peanut-patch group vs 9.3% in the placebo group. Conclusions and Relevance: Among peanut-allergic children aged 4 to 11 years, the percentage difference in responders at 12 months with the 250-μg peanut-patch therapy vs placebo was 21.7% and was statistically significant, but did not meet the prespecified lower bound of the confidence interval criterion for a positive trial result. The clinical relevance of not meeting this lower bound of the confidence interval with respect to the treatment of peanut-allergic children with epicutaneous immunotherapy remains to be determined. Trial Registration: ClinicalTrials.gov Identifier: NCT02636699.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2019.1113

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 276

Metadata

Authors
Fleischer, D. M., Greenhawt, M., Sussman, G., Bégin, P., Nowak-Wegrzyn, A., Petroni, D., Beyer, K., Brown-Whitehorn, T., Hebert, J., Hourihane, J. O., Campbell, D. E., Leonard, S., Chinthrajah, R. S., Pongracic, J. A., Jones, S. M., Lange, L., Chong, H., Green, T. D., Wood, R., Cheema, A., Prescott, S. L., Smith, P., Yang, W., Chan, E. S., Byrne, A., Assa’ad, A., Bird, J. A., Kim, E. H., Schneider, L., Davis, C. M., Lanser, B. J., Lambert, R., & Shreffler, W.
Venue
JAMA
Published
2019-03-12
Volume
321
Issue
10
Pages
946
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2916224422
Cited by
276
References
19
FWCI
23.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2019.1113
The paper
Fleischer, D. M., Greenhawt, M., Sussman, G., Bégin, P., Nowak-Wegrzyn, A., Petroni, D., Beyer, K., Brown-Whitehorn, T., Hebert, J., Hourihane, J. O., Campbell, D. E., Leonard, S., Chinthrajah, R. S., Pongracic, J. A., Jones, S. M., Lange, L., Chong, H., Green, T. D., Wood, R., . . . Shreffler, W. (2019). Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2019.1113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.